Type of Frontline Immunotherapy Does Not Affect Responses With Second-Line Cabozantinib in Advanced RCC

Patients with advanced renal cell carcinoma experienced responses to cabozantinib (Cabometyx) in the second line after receiving various frontline immunotherapy regimens, according to findings from International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) that were presented at the 2022 Genitourinary Cancers Symposium.

Additionally, investigators evaluated outcomes for patients…

Continue Reading


News Source: https://www.cancernetwork.com/view/type-of-frontline-immunotherapy-does-not-affect-responses-with-second-line-cabozantinib-in-advanced-rcc

Leave a comment

Your email address will not be published.